Monoclonal Antibodies for Hyperlipidemia: How PCSK9 Inhibitors Lower LDL Cholesterol
Episode Summary
PCSK-9 monoclonal antibodies provide powerful LDL reduction and cardiovascular protection for high-risk patients, expanding treatment options beyond statins while introducing injection, cost, and access challenges.